Bristol-Myers Squibb (BMS) is to utilise FoundationOne, Foundation Medicine’s genomic profiling and molecular information solutions, to identify predictive biomarkers in patients enrolled in clinical trials assessing BMS’s cancer immunotherapies.
Predictive biomarkers to be identified include tumour mutational burden and microsatellite instability. According to Foundation Medicine those biomarkers can be measured without the need for whole-exome sequencing through the advanced and proprietary algorithms of its FoundationOne® assay.
FoundationOne can expand treatment options by identifying genomic alterations associated with targeted therapies, quantifying clinical markers associated with immunotherapy response, and identifying relevant clinical trials.
Melanie Nallicheri, Foundation Medicine’s chief business officer and head, Biopharma, said: “Our collaboration with BMS highlights the potential value of our molecular information platform to the biopharma industry for its ability to inform, to reduce risk, and to accelerate clinical development in this high-growth and highly competitive oncology field.”
BMS’s cancer immunotherapy portfolio includes the two blockbuster treatments Opdivo® (nivolumab), and Yervoy® (ipilimumab).
BMS also recently joined the Parker Institute for Cancer Immunotherapy and the Cancer Research Institute in launching a clinical research partnership designed to speed up discovery and development of new immuno-oncology treatments.